Xi Chen Lin
Vermogen: 3 M $ op 31-05-2026
Vermogen: 3 M $ op 31-05-2026
Dr. Xi Chen Lin is a Chief Scientific Officer & GM-Structure Shanghai at Structure Therapeutics, Inc. and a General Manager at Shanghai ShouTi Biotechnology Co. Ltd. Dr. Lin was previously employed as a Head-Asia Pacific External Innovation by Novo Nordisk A/S.
He received his undergraduate degree from Peking University and a doctorate degree from The Pennsylvania State University.
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 25-06-2026 | 228.960 ( 0,16% ) | 3 M $ | 31-05-2026 |
| Bedrijven | Functie | Begin |
|---|---|---|
| STRUCTURE THERAPEUTICS INC. | Hoofd Techniek/Wetenschap/O&O | 01-07-2019 |
Shanghai ShouTi Biotechnology Co., Ltd.
Shanghai ShouTi Biotechnology Co., Ltd. BiotechnologyHealth Technology Develops biotechnologies | Algemeen Directeur | - |
| Bedrijven | Functie | Einde |
|---|---|---|
| NOVO NORDISK A/S | Corporate Officer/Principal | 01-07-2019 |
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
| Bedrijven in privébezit | 5 |
|---|---|
Novo Nordisk A/S
Novo Nordisk A/S Pharmaceuticals: MajorHealth Technology Manufactures and markets pharmaceutical products for diabetes care | Health Technology |
Peking University
Peking University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The Pennsylvania State University
The Pennsylvania State University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Structure Therapeutics, Inc.
Structure Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which develops molecule therapeutics to treat chronic diseases | Health Technology |
Shanghai ShouTi Biotechnology Co., Ltd.
Shanghai ShouTi Biotechnology Co., Ltd. BiotechnologyHealth Technology Develops biotechnologies | Health Technology |
Kies jouw editie
Alle financiële informatie op nationaal niveau